Abstract
Penile carcinoma is a rare disease, with over 95% of tumors being squamous cell carcinomas. Due to the low case numbers there has been a paucity of good-quality prospective studies available on which to base best clinical practice. The development of specialist high-volume centers in both the UK and Europe has started to permit multicenter collaboration and analysis of larger cohorts, with a knock-on improvement in patient care. Advances in diagnostic imaging, surgical techniques for both the penis and inguinal regions, and improved delivery of radiotherapy have helped to improve outcomes and quality of life. Molecular biology has started to shed light on the pathogenesis of the disease and the role that human papillomavirus may play. The aim of this article is to give an up-to-date review of the management of penile cancer encompassing the above.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
